IADR Abstract Archives
Evaluation of Biomarkers Between Restored Implants With Platform Switch or Traditional Abutment
Objectives: Platform switching (PS) concept is been used in implant therapy since 90’s; however there is still no biochemical evidence that proofs platform switch abutments are better option than the traditional ones. The primary aim of this study was to evaluate clinical peri-implant parameters, marginal bone level changes and the levels of peri-implant sulcular fluid (PISF) receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin (OPG), monocyte chemotactic protein-1 (MCP-1), Interleukin-1 beta (IL-1β). These evaluations were performed and compared in PS versus non-platform switching (NPS) abutments.
Methods: All subjects sampled in this study had at least two implants in the posterior region. Participants (n=27, 16 female - 11 male) received a clinical and radiographic examination of the implant site before the implantation. Totally 94 implants in which 47 of them as test group (PS), and the other 47 as control group (NPS) were inserted. PISF samples are taken and peri-implant health status was evaluated by plaque index (PI), bleeding on probing (BOP), and probing pocket depth (PPD) at the time of 1 week after loading (T1) and 1 year after loading (T2). PISF MCP-1, IL-1β, RANKL and OPG levels were analyzed with an enzyme-linked immunosorbent assay.
Results: The overall mean marginal bone level (MBL) change at 12 months was 0,51±0,31 mm for PS group and 0,73±0,29 mm for NPS group. Statistically significant marginal bone level change was observed between groups from T1 to T2 after loading. The amount of RANKL, OPG, MCP-1 levels increased and IL-1β levels decreased for both groups from T1 to T2. No statistically significant difference was shown for the increase of biomarkers between two measurements; except for MCP-1, the increase between two measurements in the NPS group was significantly higher than the PS group. The significant correlation between PISF OPG level and marginal bone level changes was indicated.
Conclusions: Clinical and biochemical analyses provided no evidence of a group superiority (platform switch or traditional abutments) except MCP-1. MCP-1 results were significantly low in the PS group.
Methods: All subjects sampled in this study had at least two implants in the posterior region. Participants (n=27, 16 female - 11 male) received a clinical and radiographic examination of the implant site before the implantation. Totally 94 implants in which 47 of them as test group (PS), and the other 47 as control group (NPS) were inserted. PISF samples are taken and peri-implant health status was evaluated by plaque index (PI), bleeding on probing (BOP), and probing pocket depth (PPD) at the time of 1 week after loading (T1) and 1 year after loading (T2). PISF MCP-1, IL-1β, RANKL and OPG levels were analyzed with an enzyme-linked immunosorbent assay.
Results: The overall mean marginal bone level (MBL) change at 12 months was 0,51±0,31 mm for PS group and 0,73±0,29 mm for NPS group. Statistically significant marginal bone level change was observed between groups from T1 to T2 after loading. The amount of RANKL, OPG, MCP-1 levels increased and IL-1β levels decreased for both groups from T1 to T2. No statistically significant difference was shown for the increase of biomarkers between two measurements; except for MCP-1, the increase between two measurements in the NPS group was significantly higher than the PS group. The significant correlation between PISF OPG level and marginal bone level changes was indicated.
Conclusions: Clinical and biochemical analyses provided no evidence of a group superiority (platform switch or traditional abutments) except MCP-1. MCP-1 results were significantly low in the PS group.